Related references
Note: Only part of the references are listed.Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study
Faouzi Djebbari et al.
HEMATOLOGY (2022)
Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma
Meletios Dimopoulos et al.
BLOOD (2021)
External validation of the FIRST trial's simplified frailty score in a population-based cohort
Hira S. Mian et al.
LEUKEMIA (2021)
Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
Fredrik Schjesvold et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
Thierry Facon et al.
LEUKEMIA (2020)
Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age
Monika Engelhardt et al.
HAEMATOLOGICA (2020)
A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study
Gordon Cook et al.
LANCET HAEMATOLOGY (2019)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Michel Attal et al.
LANCET (2019)
A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients
Monika Engelhardt et al.
HAEMATOLOGICA (2017)
A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients
Monika Engelhardt et al.
HAEMATOLOGICA (2017)
Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores
Monika Engelhardt et al.
HAEMATOLOGICA (2016)
Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores
Monika Engelhardt et al.
HAEMATOLOGICA (2016)
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
Antonio Palumbo et al.
BLOOD (2015)
Share Paper
